$130MSeries D, 5 February 2026
Series D to advance its musculoskeletal pipeline through mid-stage trials.
- Amount
- $130M
- Stage
- Series D
- Announced
- 5 February 2026
- Lead
- Frazier Life Sciences
- Other investors
- Venrock Healthcare Capital Partners
- Use of funds
- Series D to advance its musculoskeletal pipeline through mid-stage trials.
- Checked
- Announced by the company
- Sources
- Angitia Biopharma raises $130M Series D for bone therapeutics biospace.com
Angitia Biopharma raises $130M Series D for bone therapeutics techstartups.com